Personalis, Inc.PSNL

Personalis, the cancer-assay outfit promising ‘the most sensitive detection’ for ctDNA-based cancer insights, disclosed a quarter that left the platform story intact and the cash flow statement in tatters: revenue of $15.5 million for the three months to 31 March 2026 was enough to cover less than half of its $32.2 million operating loss, while net income came in at negative $30.0 million. Diluted earnings per share were 29 cents to the downside, and the company burned $22.5 million in operating cash during the period. Assets stood at $325.4 million against liabilities of $70.6 million, leaving shareholders’ equity at $254.8 million, of which $73.6 million was in cash and $159.6 million in short-term investments.

The company’s own website still pitches ‘advanced ctDNA technologies enabling cancer insights from molecular residual disease to therapy selection,’ but the filing tells a plainer tale: headcount and R&D spend aren’t yet translating into profitable volume, and $14.5 million of the quarter’s outgo went straight into research and development. With just $3.2 million spent on property, plant and equipment, it’s clear Personalis is still in build-and-test mode, not harvest-and-scale mode. The Tempus deal, announced on 20 July 2026, offers a $16.25-per-share exit at a 6% premium to the last close and a 28% premium to the 30-day volume-weighted average price, but the merger agreement is subject to shareholder and regulatory approval, with an earliest close in the fourth quarter of 2026.

Personalis’ assay may be the star turn in Tempus’ product suite, according to the transcript of the 20 July call, where Tempus execs called the assay’s performance ‘fantastic’ and noted that 10% of the sales force is currently directed at Personalis. Yet the same filing is candid about the risks: shareholder adoption of the merger agreement isn’t guaranteed, regulators may yet stumble, key personnel may bolt, and third-party customers could drift away. The document also nods to AI being embedded in products and services while warning that adverse economic conditions and other factors detailed in the 2025 10-Ks could derail progress.

Tempus isn’t paying cash for Personalis; it’s floating a stock exchange ratio based on its own shares, meaning Personalis shareholders will become minority owners of a larger, privately held entity whose own financials remain out of public view. For now, investors can track Personalis’ filings on EDGAR under CIK 1527753, where the latest 10-Q and the slew of 425s and 8-Ks from 20 July 2026 are all publicly available. The company’s investor relations page at www.personalis.com remains the primary conduit for the Tempus slide deck and the deal documents, though the substance is already embedded in the SEC submissions. If you want the raw numbers, the companyfacts JSON for Personalis is also on the SEC data site, but the punchline remains the same: the assay story is still winning the pitch, while the cash-flow statement is still losing.

What changed this week: the Tempus merger announcement, the 425s, the 8-K, and the Schedule 13D/A from the company’s largest shareholder. What hasn’t changed: the operating loss, the cash burn, the reliance on short-term investments, and the dependency on a deal that may not close until late 2026. If you’re looking for a chart, the SEC filings are your best bet for context; the evidence set doesn’t supply TradingView levels, and inventing them would be a disservice to readers. What would deepen the file: a clear timeline for regulatory approvals, signed customer contracts beyond the Tempus pipeline, and any disclosure that narrows the gap between assay promise and cash collection.